NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
Werbung Aktien in diesem Artikel Nanobiotix SA10,76 EUR 0,65% ChartsNewsAnalysen Aktien in diesem Artikel anzeigen Nanobiotix SA10,76 EUR 0,65% ChartsNewsAnalysen Hier für 0 € handeln Alle anzeigen Regulatory News: This press release features multime ...